EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Open Access · CC BY-NC-ND 4.0

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pimavanserin as an Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE-2) in Patients With Predominant Negative Symptoms

Dragana Bugarski-Kirola, I-Yuan Liu, Celso Arango, Stephen R Marder iD

Schizophrenia Bulletin · 2026

DOI: 10.1093/schbul/sbaf034 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Schizophrenia Bulletin, 2026. Verfasst von Dragana Bugarski-Kirola und 3 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Research, Acadia Pharmaceuticals GmbH, Basel, Switzerland. Hauptthemen laut MEDLINE: Schizophrenia, Piperidines, Urea, Antipsychotic Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Acadia Pharmaceuticals Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Hypotheses Negative symptoms of schizophrenia (NSS) carry a substantial burden, and there are no treatments currently approved for NSS. The efficacy of pimavanserin, a selective 5-HT2A inverse agonist and antagonist, in treating NSS was assessed. Study Design ADVANCE-2 was a phase 3, randomized, double-blind, placebo-controlled study of pimavanserin in patients with schizophrenia and predominantly negative symptoms. Patients were randomized (1:1) to receive pimavanserin (34 mg/day) or placebo alongside ongoing background antipsychotic medication. Eligible adults were aged 18–55 years and had access to a caregiver. The primary and key secondary endpoints were the change from baseline to week 26 in the Negative Symptom Assessment–16 (NSA-16) total score and Clinical Global Impression–Schizophrenia Scale-Severity (CGI-SCH-S) negative symptom score, respectively. Study Results Of the 454 randomized patients, 71 (39 placebo; 32 pimavanserin) discontinued and 383 (188 placebo; 195 pimavanserin) completed the study. The safety and full analysis sets comprised 453 and 446 patients, respectively. The NSA-16 change from baseline to week 26 was not significantly different between groups (least squares mean difference: −0.67; SE, 0.95; [95% CI: −2.54, 1.20]; P = .48; Cohen’s d effect size: 0.07). Treatment-emergent adverse events occurred in 30.4% with pimavanserin and 40.3% with placebo. Conclusions In this study, pimavanserin was well tolerated, and although it demonstrated a similar treatment effect as in the prior phase 2 study favoring pimavanserin, treatment with pimavanserin vs placebo did not result in significant differences for primary or other endpoints.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SchizophreniaPiperidinesUreaAntipsychotic AgentsOutcome Assessment, Health CareSerotonin 5-HT2 Receptor AntagonistsHumansAdultDouble-Blind MethodMaleFemaleMiddle AgedYoung AdultAdolescentDrug Therapy, Combination

Stichwörter der Autor:innen

atypical antipsychotic5-HT2ANSA-16Serotonin 5-HT2 receptor antagonistsanhedoniaavolition

Substanzen

pimavanserinPiperidinesUreaAntipsychotic AgentsSerotonin 5-HT2 Receptor Antagonists

Autor:innen und Institutionen

  • Clinical Research, Acadia Pharmaceuticals GmbH, Basel, Switzerland.
  • Acadia Pharmaceuticals Inc., San Diego, CA, USA.
  • Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón, IiSGM, School of Medicine, Universidad Complutense, Madrid, Spain.
  • Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain.
  • Semel Institute for Neuroscience, University of California Los Angeles, Los Angeles, CA, USA.

ORCID-Profile: Stephen R Marder

Förderung

  • Acadia Pharmaceuticals Inc

Zitieren

APA

Bugarski-Kirola, D., Liu, I. Y., Arango, C., & Marder, S. R. (2026). A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pimavanserin as an Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE-2) in Patients With Predominant Negative Symptoms. Schizophrenia Bulletin. https://doi.org/10.1093/schbul/sbaf034

Vancouver

Bugarski-Kirola D, Liu IY, Arango C, Marder SR. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pimavanserin as an Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE-2) in Patients With Predominant Negative Symptoms. Schizophrenia Bulletin. 2026. doi:10.1093/schbul/sbaf034

BibTeX
@article{BugarskiKirola2026,
  author = {Bugarski-Kirola, Dragana and Liu, I-Yuan and Arango, Celso and Marder, Stephen R},
  title = {A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pimavanserin as an Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE-2) in Patients With Predominant Negative Symptoms},
  journal = {Schizophrenia Bulletin},
  year = {2026},
  doi = {10.1093/schbul/sbaf034}
}
Kostenlos starten →